Supporting this reasoning, profiling of circulating sphingolipids uncovered that pioglitazone treatment in people with metabolic syndrome induced a potent decrease in plasma ceramides and that some of those changes correlated with changes in adiponectin levels and insulin resistance (42, 43). Here, ADIPOQ is linked to Insulin resistance.